When the pie is too small by Petsko, Gregory A
Thirty-two billion US dollars is a lot of money. It’s more 
than the gross national product of Kuala Rokat, a non-
existent but real-sounding country. If it were in pennies 
the resulting stack of 3.2 trillion coins would be roughly 
5  billion  meters  high,  tall  enough  to  reach  from  the 
surface of the earth roughly a tenth of the way to Mars. In 
one dollar bills, which don’t weigh more than a gram, it 
would  weigh  about  three  times  as  much  as  the  Eiffel 
Tower.  Any  way  you  express  it,  it’s  a  mighty  big  pie. 
Unfortunately, it’s not big enough.
The Congress of the United States is currently debating 
the budget for the National Institutes of Health (NIH), 
the world’s largest provider of research funding for bio-
medical  science  in  general  (and  genome  biology  in 
particular), and $32 billion is the figure they are currently 
recommending for fiscal year 2011. If that is the number 
ultimately  awarded,  the  biomedical  science  research 
community in the US is going to face some agonizing 
choices.
Before  the  stimulus  funding  of  2009-2010,  the  NIH 
budget was $30 billion. $32 billion would represent an 
increase,  but  one  substantially  less  than  the  level  of 
scientific inflation, which has been averaging about 6% a 
year over the past few years. And the base budget was too 
small  already  back  then,  because  of  years  of  declining 
funding (in inflation-adjusted dollars) under George W 
Bush. The Federation of American Societies for Experi-
mental Biology (FASEB) estimated that $37 billion would 
be needed to bring the budget up to where it should be, 
and to avoid what some are calling a ‘cliff’ in funding as 
the $10 billion in stimulus money that was added to the 
base budget last year runs out. My personal view was that 
we needed something as close to $40 billion as we could 
get. $32 billion isn’t close at all.
Things could change before the final budget is passed, 
but  I  doubt  it.  Congress  is  scared  to  death  about  the 
burgeoning US deficit, which is stupid because we are in 
a  deep  recession  with  close  to  double-digit  unemploy-
ment  and  a  real  interest  rate  close  to  zero.  Keynesian 
economics  tells  you  that  in  such  a  situation,  where 
monetary policy is useless because interest rates cannot 
go negative, the government should be spending more, 
not less. And spending money on scientific research is 
particularly  smart,  because  it  has  been  estimated  that 
every  dollar  spent  that  way  rapidly  produces  2.0-2.5 
dollars of economic output, one of the highest multipliers 
for  any  form  of  government  investment.  But  the  US 
Congress has been remarkably spineless of late, and in 
the face of calls for fiscal restraint by the political right, it 
seems  unlikely  that  we  will  see  an  increase  in  the 
proposed amount for the NIH.
There’s another reason not to expect much, and that’s 
because the Democrats are in power. I know, it seems 
ridiculous  that  Barack  Obama’s  administration,  which 
actually respects science and listens to its advice, would 
leave biomedical research high and dry, but I think they 
will. Democratic administrations usually do. The problem 
isn’t that they don’t love science, it’s that they love their 
favorite  social  programs  more,  and  there  simply  isn’t 
enough  money  to  fund  both  at  the  level  they  are 
clamoring for. The odd thing about US politics (okay, one 
of many odd things) is that, with the exception of the 
anti-intellectual,  science-phobic  Bush  administration, 
Republican governments have been friendlier to scientific 
research,  in  terms  of  funding,  than  their  Democratic 
counterparts. Republicans have largely bought the idea 
that  funding  research,  including  ‘basic’  research,  helps 
the competitiveness of the country and jump-starts new 
businesses. There will be a lot more money under Obama 
for  energy  research  (the  Democrats  have  completely 
accepted the idea that global warming is a huge problem), 
but that may well be at the expense of money for the life 
sciences.
What, then, does a $32 billion NIH budget mean for 
American science? If present trends in funding priorities 
continue,  it  means  that  the  number  of  individual 
investigator-initiated grants (called ‘R01s’ in NIH-speak) 
is  going  to  shrink  dramatically,  as  the  bureaucrats  in 
Washington use the precious dollars first to maintain - 
and  possibly  expand  -  their  pet  big  science  programs. 
Keeping the cancer genome program and the structural 
genomics  program  and  the  genome-wide  association 
studies afloat will require that the R01 pool shrink, and it 
is already, in percentage terms, dangerously low. © 2010 BioMed Central Ltd
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Society for Biochemistry and Molecular Biology, has put 
together  some  initial  data  that  illustrate  this  looming 
crisis. Using the total number of R01s and investigators 
in a given year, he has calculated the average number of 
R01 grants per investigator from 1965 to 2005. The data 
were  obtained  from  the  NIH  RePORT  website  (http://
report.nih.gov/index.aspx; specifically http://grants2.nih.
gov/grants/new_investigators/New_Invest_Grants_and_
Numbers.xls).
In  2005,  the  average  number  of  R01-equivalents  per 
investigator was 1.35. This average has climbed steadily 
since 1970, when it was 1.12, and its rate of increase has 
become steeper since the 7-year NIH budget doubling 
began in the late 1990s. One interpretation of this trend 
is that proportionally more principal investigators (PIs) 
are able to obtain more than one grant than they were in 
1970. This trend accelerated during the doubling. Taking 
this further, it suggests that as the budget has increased, 
the NIH is putting more of its money into proportionally 
fewer labs.
The distribution of grants per investigator looks expo-
nential and has a mode of 1 (the most investigators have 
one grant, the second most have two, the third most have 
three, and so on). But perhaps even more important is 
the dollar amount, because it is the finite pie that we’re 
talking  about  here.  During  the  past  10  years,  a  small 
number of laboratories and groups of laboratories have 
been  receiving  an  increasing  share  of  that  pie,  as  big, 
expensive  data-gathering  projects  and  programs  have 
increased at the expense of single-investigator hypothesis-
driven research grants.
These numbers show why all scientists should fear for 
the R01 pool in a time of disastrously small budgets. I am 
not  sanguine  that  most  of  the  directors  of  the  NIH 
institutes  and  centers,  who  control  their  individual 
budgets, are going to be able to resist the temptation to 
protect the most visible, glamorous, and disease-related 
work while letting the number of ‘basic’ science projects 
shrink. It is, therefore, incumbent on us to offer them 
solutions to the small-pie problem that keep that from 
happening. Here are some ways that have been suggested 
of  cutting  the  pie  into  more  slices,  predicated  on  the 
assumption - which seems entirely reasonable to me - 
that it is better to give an investigator with a good idea 
some money than no money at all.
(1) Impose a cap on the maximum dollar amount per R01 
grant for direct and, more importantly, indirect costs. 
The  former  are  the  dollars  that  actually  go  to  the 
investigator(s); the latter are the dollars that go to the 
institution  to  cover  the  costs  of  administering  the 
grant. Indirect cost rates range from around 20% of 
total direct costs to over 100% (and yes, that’s not a 
typo), so a $1 million grant spread over 5 years can 
actually end up costing the NIH $1.5 million or more. 
The problem with this strategy is that most research 
universities, and medical schools in particular, live on 
indirect costs, and an abrupt shutoff of the pipeline 
could starve them.
(2) It may be necessary to make people with special long-
term sources of funding, such as those with research 
chairs that supply large amounts of research dollars, 
or  Investigators  of  the  Howard  Hughes  Medical 
Institutes, ineligible for more than one R01 grant on 
top  of  their  other  funding.  An  exception  could  be 
made if they were in the 3-year transition period after 
being dropped as a Howard Hughes Investigator, or 
were about to lose the special funds for any reason. 
How  to  determine  whether  there  is  enough  special 
funding to trigger such a restriction is not obvious to 
me.
(3) Impose a cap on the maximum number of R01 total 
dollars per PI. I have no idea how to set that figure 
fairly given the vastly different costs of clinical and 
non-clinical research, but maybe someone else will.
(4) Reduce  the  maximum  duration  of  an  R01  grant 
(currently 4-5 years) to perhaps 3-4 years. The burden 
this will place on scientists will be considerable, given 
that  they  already  spend  a  huge  percentage  of  their 
time writing grants now.
(5) Impose a limit of no more than one R01 equivalent 
per PI from any one NIH institute. That would have 
the advantage of forcing scientists to become more 
interdisciplinary,  and  the  disadvantage  of  flooding, 
say, the National Cancer Institute with applications 
from people who know nothing about cancer.
(6) Award  percentages  of  recommended  budgets 
according to how highly a proposal was rated by the 
grants  review  panel.  Thus,  the  top  5%  of  proposals 
would  receive  100%  of  their  recommended  (not 
requested)  budget;  the  next  5%  would  receive  75%, 
the next 5% 65%, and the next 5% 50%. This is the 
solution I prefer, as it rewards quality while stretching 
the research dollars to cover more investigators.
Any  of  these  provisions  would  need  to  be  reversible 
pending a better funding climate. Given the difficulty in 
ending any government program, that may be harder to 
carry out than the actual spending restrictions, which is 
another reason I prefer solution 6 above; it would have 
the  least  severe  long-term  consequences.  The  commit-
ment for each institute and center could be to aim for a 
payline  of,  say,  20%  of  recommended  R01  proposals 
receiving funding, which they would achieve by cutting 
and/or modifying spending using some combination of 
these provisions as necessary. (My friend John Kyriakis 
owlishly points out that the political climate is just right 
to  get  such  ideas  implemented.  NIH  could  claim  it  is 
contributing to ‘reducing big government’.)
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terminate some of the pie-hogging big science programs 
and put the savings into the R01 pool. That’s what we 
should in fact do, so I guess there really isn’t a hope in 
hell that we will.
By the way, $32 billion is exactly the sum that BP has 
been forced to pay by the US government as a penalty for 
the Gulf of Mexico oil spill. I don’t know whether to laugh 
at that coincidence or just cry.
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